Navire Pharma

Biotech · Private

Small molecule inhibitors targeting SHP2 and RAS pathway proteins for RAS/MAPK-driven solid tumors

navirepharma.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
15
4 granted · 11 pending
Sector median: 2

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2976CAMBIUM ONCOLOGY LLC——
2977MEDICATIONS DISCOVERY TEXAS, INC.——
2978BOLDEN THERAPEUTICS, INC.——
2979Navire Pharma——
2980POW GENETIC SOLUTIONS, INC.——
2981QUORUM INNOVATIONS, LLC——
2982NuPeak Therapeutics, Inc.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 4 granted of 15
  • Combination Therapy Using A Substituted PYRIMIDIN-4(3H)-ONE And Nivolumab As Well As Its Use In The Treatment Of Cancerapplication
  • Substituted PYRIMIDIN-4(3H)-ONES For Use In Treating Cancerapplication
  • PTPN11 Inhibitorsgranted
  • Substituted Heterocyclic Inhibitors Of PTPN11granted
  • PTPN11 Inhibitorsgranted
  • Substituted Heterocyclic Inhibitors Of PTPN11granted
  • Treatment Methods With Substituted PYRIMIDIN-4(3H)-ONESapplication
  • Treatment Methods With Substituted PYRIMIDIN-4(3H)-ONESapplication
  • PTPN11 Inhibitorsapplication
  • Combination Therapy Using A Pyrimidone Derivative As PTPN11 Inhibitor And A PD-1/PD-L1 Inhibitor And Its Use In The Treatment Of Cancerapplication
  • PTPN11 Inhibitorsapplication
  • Treatment Methods With Substituted PYRIMIDIN-4(3H)-ONESapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.